Featured Story | By Ben Adams A biotech with a long and often troubled past is hoping 2021 will be its year, and it’s just been handed a major tranche of cash to help make that happen. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor AstraZeneca has stopped development of its anti-BCMA antibody-drug conjugate (ADC) in multiple myeloma. The Anglo-Swedish drugmaker was set to take MEDI2228 into phase 2 this year but has opted against forging ahead in the congested BCMA space. read more By Annalee Armstrong As Vaccitech prices a $110.5 million IPO, one long-time investor says the company has a pipeline that could address a number of killer diseases long after the headlines over the AstraZeneca vaccine’s blood clot concerns fade. read more Sponsored By: Parexel Biotech A well-thought-out strategic development plan that brings together nonclinical, clinical, regulatory and commercial experts can improve efficiencies, cut costs, shorten timelines, and increase the chances of success for a new drug program. read more By Amirah Al Idrus As it chases its shape-shifting cytokine drugs toward the clinic, Werewolf Therapeutics will collect $120 million in its Wall Street debut. After snaring a $72 million private round in January, it filed to raise up to $100 million in its IPO. The company bumped that up to $120 million by upping the number of shares it would offer. read more By Nick Paul Taylor A phase 2 trial of Cara Therapeutics’ anti-itch treatment has missed its primary endpoint, sending the biotech’s stock price down 45%. Yet, Cara is forging ahead in atopic dermatitis on the strength of an efficacy signal in patients with mild-moderate disease. read more By Eric Sagonowsky Amgen and Sanofi aren't the only two drugmakers threatened by their high-stakes PCSK9 patent fight. After Amgen suffered a pair of setbacks in the case, GlaxoSmithKline became the latest Big Pharma to weigh in, this time arguing a recent court decision could "devastate" pharma R&D incentives. read more By Arlene Weintraub Zebrafish can recover from spinal cord injuries, thanks to a healing process that’s controlled by immune cells called macrophages. Researchers from the University of Edinburgh the gene editing technology CRISPR-Cas9 to identify four genes that are crucial for repairing severed spinal cords. read more By Conor Hale To avoid fighting a two-front, international legal battle over its pursuit of the cancer tester Grail, Illumina has asked judges to step in and halt the European Commission’s review of the proposed $8 billion deal. read more By Fraiser Kansteiner Two big name cancer R&D vets have teamed up to form a new oncology biotech. GV, formerly known as Google Ventures, signed on its first executive venture partner. And MiMedx tapped Dirk Stevens as SVP of quality assurance and regulatory affairs. read more By Angus Liu Gilead Sciences and Merck chipped in to help India cope with a surge of COVID-19. BeiGene's Brukinsa reported positive results in a head-to-ahead study against Imbruvica. Astellas took a $540 million impairment related to its Audentes Therapeutics gene therapy buy. And more. read more Resources Sponsored by: Datacubed Health The average clinical trial spends $40,000 per patient. Yet despite these high costs, most trials struggle to retain patients. Sponsored By: AmerisourceBergen Developing a quality product and getting it approved for distribution is not enough to guarantee commercial success. Sponsored By: WCG Trifecta The new standards in study training help sponsors and CROs reduce costs by 60%, cut training time by 50%, and start enrollment 55 days faster – learn more today. Sponsored By: Oracle Health Sciences New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19. Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process intesification Sponsored By: August Bioservices How has COVID-19 impacted CRO/CDMO customer (dis)satisfaction and outsourcing decisions for pharma and biotech companies in 2021 and beyond? Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process development and manufacturing of your novel molecule Sponsored by: PerkinElmer Informatics Discover the benefits of a cloud-native ELN that delivers better performance, security, connectivity, total cost of ownership PLUS sub-second search results through even the largest data volumes. Sponsored By: Within3 We enable virtual work — offering over-time sessions where participants are more focused, insights are more diverse and business goals are met. Sponsored by: TAC Roche has inked a $1.8 billion, all-cash deal for GenMark Diagnostics, to acquire its molecular tests designed to screen patient samples for multiple infections simultaneously. Sponsored By: Remarque Systems Remarque Systems consolidates data, then layers on visualization and automated metrics to generate consistent, actionable data insights in real-time. Click here for more info. Sponsored By: Culture Biosciences Find out how upstream bioprocess scientists can use Culture Biosciences’ bioreactor system and real-time data visualizations to get faster insights and get their product to market more quickly. Sponsored By: BC Platforms Those wishing to unlock RWD’s true value must have access to a variety of data sources/types and the technological capabilities to use the data to uncover meaningful insights. Sponsored By: Oracle Health Sciences New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19. Sponsored by: Catalent Autologous cell therapies have seen propelled growth since 2017, with the spotlight on the first FDA approval of a chimeric antigen receptor (CAR) T cell immunotherapy, Kymriah® (tisagenlecleucel), for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. Sponsored by: Catalent In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. | 
